NASH Drug Development Questions? US FDA Has Many Of The Answers
Executive Summary
From biomarkers to treatment effect size, agency officials respond to some of more than a hundred questions that poured in during a webinar on development of drugs to treat the liver disease.
You may also be interested in...
US FDA Liver Drug Division Acting Director Is Frank Anania
The former Emory professor is now leading the US FDA Division of Hepatology & Nutrition after its inaugural director, Joseph Toerner, moves back to the infectious disease field as acting deputy in FDA’s vaccines office.
Inventiva Revises Phase III NASH Plans For Broader Indication
While plans to obtain accelerated approval of lanifibranor remain unchanged, Inventiva now plans to conduct the confirmatory Phase III in cirrhotic patients, meaning a shorter trial duration and possibly broader label.
Pharma’s Digital Pathology Build-Out; Part 1 – The State Of Play
Pharma companies are applying digital pathology throughout their research and development functions. Where are they now finding value?